SCHEMBL2648124

SCHEMBL2648124

CCCOC1CCC(NC2CCCCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 1/20 0.46
THRB P10828 1/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
EPHX2 P34913 2/20 0.34
KDM4E B2RXH2 2/20 0.33
EPHX1 P07099 2/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648802 1.00 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648807 1.00 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648247 1.00 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648122 1.00 ALDH1A1 (0.46) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648216 0.98 ALDH1A1 (0.42) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2648219 0.98 ALDH1A1 (0.42) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2649659 0.86 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2647838 0.86 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2647840 0.86 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1
SCHEMBL2649655 0.86 ALDH1A1 (0.52) ALDH1A1HSD17B10THRBATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
CN-101258137-A Dicycloalkyl urea glucokinase activators NOVO NORDISK AS (DK) 2008-09-03 CN disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
CN-1910166-A Heteroaryl ureas and their use as glucokinase activators NOVO NORDISK AS (DK) 2007-02-07 CN disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 ALDH1A1 3782/4885HSD17B10 1699/4885THRB 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.